Intelligent Medicine Acquisition Corp. (IQMDU) Prices Upsized $180M IPO

Intelligent Medicine Acquisition Corp. announced the pricing of its upsized $150 million IPO and its units are expected to begin trading on the Nasdaq under the symbol “IQMDU” Friday, November 5.

The new SPAC intends to focus on life science companies that are using artificial intelligence, machine learning and big data to power drug discovery. Intelligent Medicine is led by CEO and CFO Gregory C. Simon and Chairman Jack D. Hidary.

Total SPAC deal count for 2021 year-to-date is now 523. This offering is expected to close on Tuesday, November 9.

Cantor Fitzgerald & Co. is the sole book running manager for the offering. Paul Hastings LLP is serving as Issuer’s Counsel with Ellenoff Grossman & Schole LLP serving as Underwriter’s Counsel.  Marcum, LLP serves as auditor. Continental Stock Transfer & Trust Company is acting as trustee.